India, April 7 -- Sun Pharmaceutical Industries Limited (NSE: SUNPHARMA | BSE: 524715) has announced the launch of FEXUCLUE® (Fexuprazan) 40 mg tablets in India, offering a novel treatment option for adults suffering from Erosive Esophagitis of all grades. FEXUCLUE® is a next-generation potassium-competitive acid blocker (PCAB) that introduces a new therapeutic class in the Indian market.
The drug is being introduced under a licensing agreement with Daewoong Pharmaceutical Co. Ltd., Korea, which grants Sun Pharma the rights to manufacture and commercialize FEXUCLUE® in India. As part of the agreement, Daewoong will receive upfront payments, milestone-based payments, and royalties.
Speaking on the launch, Kirti Ganorkar, CEO &n...